Skip to Content

Farxiga (dapagliflozin) Disease Interactions

There are 4 disease interactions with Farxiga (dapagliflozin):

Major

Dapagliflozin (Includes Farxiga) ↔ bladder cancer

Severe Potential Hazard, Moderate plausibility. Applies to: Bladder Cancer

There is insufficient evidence to determine if dapagliflozin has an effect on preexisting bladder tumors or if it can cause bladder cancer. However, the manufacturer does not recommend the use of dapagliflozin in patients with active bladder cancer. In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.

Major

SGLT-2 inhibitors (Includes Farxiga) ↔ renal dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

The glucose lowering effects of SGLT-2 inhibitors is decreased in patients with worsening renal function. Additionally, SGLT-2 inhibitors increase serum creatinine and decrease eGFR. The elderly and patients with moderate renal impairment are at increased risk of further renal dysfunction. Renal function should be evaluated before treatment initiation and monitored regularly in these patients. The use of SGLT-2 inhibitors in patients with severe renal impairment, end stage renal dysfunction (ESRD), or undergoing dialysis is contraindicated. Based on its mechanism of action, SGLT-2 inhibitors are not expected to be effective in patients with this level of renal dysfunction.

Moderate

SGLT-2 inhibitors (Includes Farxiga) ↔ hyperlipidemia

Moderate Potential Hazard, Moderate plausibility. Applies to: Hyperlipidemia

There have been reports of dose-related increases in LDL cholesterol with the use of SGLT-2 inhibitors. Cholesterol levels should be monitored before and during treatment and appropriate therapy should be initiated if needed.

Moderate

SGLT-2 inhibitors (Includes Farxiga) ↔ Hypotension

Moderate Potential Hazard, High plausibility. Applies to: Hypotension, Renal Dysfunction

SGLT-2 inhibitors cause intravascular volume contraction and symptomatic hypotension may occur after treatment initiation especially in the elderly, in patients with impaired renal function, low systolic blood pressure, or using diuretics . Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.

Farxiga (dapagliflozin) drug interactions

There are 335 drug interactions with Farxiga (dapagliflozin)

Farxiga (dapagliflozin) alcohol/food interactions

There are 2 alcohol/food interactions with Farxiga (dapagliflozin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide